Levaquin Tendon Damage Trial Underway in New Jersey State Court

Trial has begun in New Jersey state court for two lawsuits that alleges Johnson & Johnson failed to adequately warn doctors and patients about the risk of tendon damage from side effects of Levaquin, a popular antibiotic that has been the subject of more than 2,600 similar lawsuits filed throughout the United States.

A jury in Atlantic City will hear the combined trial involving Levaquin lawsuits filed by Paul Gaffney and Robert Beare, who allege they each suffered tendon ruptures after taking the antibiotic. Plaintiffs are expected to argue that their injuries could have been avoided if Johnson & Johnson had placed a stronger warning on the label before they used Levaquin, instead of downplaying the risks.

Johnson & Johnson contends that are not liable for the men’s injuries because there were warnings on Levaquin labels about the risk of tendon damage since the antibiotic was first approved by the FDA in 1996. The company’s attorneys also contend that Gaffney, 67, and Beare, 72, had other symptoms that could have cause their tendon ruptures and claims the men did not follow their doctors’ advice, which may have prevented the ruptures.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

In July 2008, the FDA required that a “black box” warning be added about the side effects of Levaquin and other similar antibiotics, which is the strongest warning that can be placed on a prescription medication. However, consumer advocates called for stronger Levaquin tendon rupture warnings to be added at least two years earlier, with Public Citizen filing a petition with the FDA in 2006, insisting that consumers and the medical community be provided with clearer warnings about the risk of tendon damage.

Although this is the first Levaquin trial to begin in New Jersey state court, where about 1,900 of the cases are currently pending, it is the third trial over Levaquin tendon damage to reach a jury in the U.S. Two prior bellwether trials have been held in federal court, where the Levaquin litigation has been consolidated for pretrial proceedings as part of an MDL, or multidistrict litigation, in the U.S. District Court for the District of Minnesota.

In December, a federal jury ruled that the drug makers failed to adequately warn about the risk of Levaquin tendon ruptures, and awarded the plaintiff in that case, John Schedin, $1.8 million in damages. However, in June a different jury sided with Johnson & Johnson, saying that the label warnings were adequate enough to reject 84-year-old Calvin Christensen’s Levaquin tendon rupture claim.

Although these early Levaquin trials are not binding on any other cases, they are closely watched by parties involved, as they provide a good gauge for how juries may respond to similar evidence that will be presented throughout other cases in the litigation. The outcome of the early trials may help facilitate a potential Levaquin settlement agreement for other cases that are pending.


  • Courtroom View NetworkSeptember 8, 2011 at 2:14 am

    The full Levaquin trial in New Jersey is being webcast live online via Courtroom View Network. You can sign up to watch gavel-to-gavel video of the full proceedings at http://www.courtroomview.com

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.

Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant
Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant (Posted 2 days ago)

Following a $60 million verdict in a similar lawsuit earlier this year, trial is underway involving claims brought by an Illinois mother, whose premature daughter developed NEC from Similac, alleging that Abbott failed to warn parents and medical staff of the devastating risks associated with the cow's milk-based formula.